Equities

Castle Biosciences Inc

CSTL:NMQ

Castle Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)33.29
  • Today's Change-0.02 / -0.06%
  • Shares traded396.27k
  • 1 Year change+85.36%
  • Beta0.9471
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy5
Outperform4
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 9 analysts offering 12 month price targets for Castle Biosciences Inc have a median target of 41.00, with a high estimate of 50.00 and a low estimate of 32.00. The median estimate represents a 23.16% increase from the last price of 33.29.
High50.2%50.00
Med23.2%41.00
Low-3.9%32.00

Earnings history & estimates in USD

On Nov 04, 2024, Castle Biosciences Inc reported 3rd quarter 2024 earnings of 0.08 per share. This result exceeded the -0.06 consensus loss of the 7 analysts covering the company and outperformed last year's 3rd quarter results by 0.34.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate-0.89%
Castle Biosciences Inc reported annual 2023 losses of -2.14 per share on Feb 28, 2024.
Average growth rate-94.45%
More ▼

Revenue history & estimates in USD

Castle Biosciences, Inc. had 3rd quarter 2024 revenues of 85.78m. This bettered the 79.84m consensus of the 9 analysts covering the company. This was 104.06% above the prior year's 3rd quarter results.
Average growth rate+8.93%
Castle Biosciences, Inc. had revenues for the full year 2023 of 219.79m. This was 60.38% above the prior year's results.
Average growth rate+44.25%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.